HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

T-cell prolymphocytic leukemia (T-PLL) is an uncommon mature T-cell neoplasm characterized by the proliferation of abnormal lymphoid cells morphologically akin to prolymphocytes. 1 However, in some ...

During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with ...

BeiGene, Ltd. , a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor ...

Major Finding: An inflammatory signature is a prognostic biomarker for CAR T-cell failure in non-Hodgkin lymphoma. Concept: InflaMix uses results from common blood tests to predict survival and ...

Notably, this patient had previously undergone 7 prior lines of therapy including chemoimmunotherapies, CD19 CAR T cells ... and refractory B-cell non-Hodgkin's lymphoma (B-NHL; NCT05370430 ...

Multiple Catholic Bishops Raise Alarm Over New Law The Cybertruck's First Real Test - And It Didn't Go Well Greer fire update: Map shows Arizona blaze spreading as emergency declared ‘The Plague ...

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Impact of ...